Clinical Trial Update: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated antithymocyte globulin and cyclosporine in low-risk myelodysplastic syndrome; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Myelodysplastic Syndrome | Phase 4 | Status: COMPLETED